Efficacy and tolerability of moexipril and nitrendipine in postmenopausal women with hypertension

E. Agabiti-Rosei, E. Ambrosioni, A. Pirelli, M. Stimpel, A. Zanchetti

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective: The aim of this study was to compare the efficacy and tolerability of the new angiotensin-converting enzyme (ACE) inhibitor moexipril and the calcium antagonist nitrendipine in postmenopausal women with mild to moderate hypertension. Methods: After a 4-week placebo run-in period, 93 postmenopausal women (age range 44-70 years) with primary hypertension were randomized to receive moexipril 15 mg once daily or nitrendipine 20 mg once daily for 8 weeks. The mean sitting systolic (SSBP) and sitting diastolic blood pressures (SDBP) at baseline were 161.3/103.0 mmHg in the moexipril group, and 162.2/ 102.3 mmHg in the nitrendipine group. Results: After the 8 weeks of treatment, the SSBP/SDBP reductions were - 21.2/-15.2 mmHg in the moexipril group and -18.2/-13.6 mmHg in the nitrendipine group. Blood pressure responses were adequate in 82.2% of the moexipril-treated patients and in 80.9% in the nitrendipine-treated group. Adverse events were more frequent with nitrendipine than with moexipril. The most common adverse events in the nitrendipine group were headache (23.4%), flushing (21.3%) and ankle oedema (14.9%). In the moexipril group the most common adverse event was cough (8.9%). Conclusion: The results of the study suggest that moexipril and nitrendipine are equieffective in the given dosages. In the patient population of postmenopausal women, the ACE inhibitor moexipril appears to have an advantage over the calcium antagonist nitrendipine with regard to tolerability.

Original languageEnglish
Pages (from-to)185-189
Number of pages5
JournalEuropean Journal of Clinical Pharmacology
Volume55
Issue number3
DOIs
Publication statusPublished - 1999

Fingerprint

Nitrendipine
Hypertension
Blood Pressure
Angiotensin-Converting Enzyme Inhibitors
Calcium
Postmenopause
moexipril
Cough
Ankle
Headache
Edema
Placebos

Keywords

  • Hypertension
  • Menopause
  • Moexipril

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Efficacy and tolerability of moexipril and nitrendipine in postmenopausal women with hypertension. / Agabiti-Rosei, E.; Ambrosioni, E.; Pirelli, A.; Stimpel, M.; Zanchetti, A.

In: European Journal of Clinical Pharmacology, Vol. 55, No. 3, 1999, p. 185-189.

Research output: Contribution to journalArticle

Agabiti-Rosei, E. ; Ambrosioni, E. ; Pirelli, A. ; Stimpel, M. ; Zanchetti, A. / Efficacy and tolerability of moexipril and nitrendipine in postmenopausal women with hypertension. In: European Journal of Clinical Pharmacology. 1999 ; Vol. 55, No. 3. pp. 185-189.
@article{c4aa170493c14b8890886c30f692a915,
title = "Efficacy and tolerability of moexipril and nitrendipine in postmenopausal women with hypertension",
abstract = "Objective: The aim of this study was to compare the efficacy and tolerability of the new angiotensin-converting enzyme (ACE) inhibitor moexipril and the calcium antagonist nitrendipine in postmenopausal women with mild to moderate hypertension. Methods: After a 4-week placebo run-in period, 93 postmenopausal women (age range 44-70 years) with primary hypertension were randomized to receive moexipril 15 mg once daily or nitrendipine 20 mg once daily for 8 weeks. The mean sitting systolic (SSBP) and sitting diastolic blood pressures (SDBP) at baseline were 161.3/103.0 mmHg in the moexipril group, and 162.2/ 102.3 mmHg in the nitrendipine group. Results: After the 8 weeks of treatment, the SSBP/SDBP reductions were - 21.2/-15.2 mmHg in the moexipril group and -18.2/-13.6 mmHg in the nitrendipine group. Blood pressure responses were adequate in 82.2{\%} of the moexipril-treated patients and in 80.9{\%} in the nitrendipine-treated group. Adverse events were more frequent with nitrendipine than with moexipril. The most common adverse events in the nitrendipine group were headache (23.4{\%}), flushing (21.3{\%}) and ankle oedema (14.9{\%}). In the moexipril group the most common adverse event was cough (8.9{\%}). Conclusion: The results of the study suggest that moexipril and nitrendipine are equieffective in the given dosages. In the patient population of postmenopausal women, the ACE inhibitor moexipril appears to have an advantage over the calcium antagonist nitrendipine with regard to tolerability.",
keywords = "Hypertension, Menopause, Moexipril",
author = "E. Agabiti-Rosei and E. Ambrosioni and A. Pirelli and M. Stimpel and A. Zanchetti",
year = "1999",
doi = "10.1007/s002280050616",
language = "English",
volume = "55",
pages = "185--189",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Efficacy and tolerability of moexipril and nitrendipine in postmenopausal women with hypertension

AU - Agabiti-Rosei, E.

AU - Ambrosioni, E.

AU - Pirelli, A.

AU - Stimpel, M.

AU - Zanchetti, A.

PY - 1999

Y1 - 1999

N2 - Objective: The aim of this study was to compare the efficacy and tolerability of the new angiotensin-converting enzyme (ACE) inhibitor moexipril and the calcium antagonist nitrendipine in postmenopausal women with mild to moderate hypertension. Methods: After a 4-week placebo run-in period, 93 postmenopausal women (age range 44-70 years) with primary hypertension were randomized to receive moexipril 15 mg once daily or nitrendipine 20 mg once daily for 8 weeks. The mean sitting systolic (SSBP) and sitting diastolic blood pressures (SDBP) at baseline were 161.3/103.0 mmHg in the moexipril group, and 162.2/ 102.3 mmHg in the nitrendipine group. Results: After the 8 weeks of treatment, the SSBP/SDBP reductions were - 21.2/-15.2 mmHg in the moexipril group and -18.2/-13.6 mmHg in the nitrendipine group. Blood pressure responses were adequate in 82.2% of the moexipril-treated patients and in 80.9% in the nitrendipine-treated group. Adverse events were more frequent with nitrendipine than with moexipril. The most common adverse events in the nitrendipine group were headache (23.4%), flushing (21.3%) and ankle oedema (14.9%). In the moexipril group the most common adverse event was cough (8.9%). Conclusion: The results of the study suggest that moexipril and nitrendipine are equieffective in the given dosages. In the patient population of postmenopausal women, the ACE inhibitor moexipril appears to have an advantage over the calcium antagonist nitrendipine with regard to tolerability.

AB - Objective: The aim of this study was to compare the efficacy and tolerability of the new angiotensin-converting enzyme (ACE) inhibitor moexipril and the calcium antagonist nitrendipine in postmenopausal women with mild to moderate hypertension. Methods: After a 4-week placebo run-in period, 93 postmenopausal women (age range 44-70 years) with primary hypertension were randomized to receive moexipril 15 mg once daily or nitrendipine 20 mg once daily for 8 weeks. The mean sitting systolic (SSBP) and sitting diastolic blood pressures (SDBP) at baseline were 161.3/103.0 mmHg in the moexipril group, and 162.2/ 102.3 mmHg in the nitrendipine group. Results: After the 8 weeks of treatment, the SSBP/SDBP reductions were - 21.2/-15.2 mmHg in the moexipril group and -18.2/-13.6 mmHg in the nitrendipine group. Blood pressure responses were adequate in 82.2% of the moexipril-treated patients and in 80.9% in the nitrendipine-treated group. Adverse events were more frequent with nitrendipine than with moexipril. The most common adverse events in the nitrendipine group were headache (23.4%), flushing (21.3%) and ankle oedema (14.9%). In the moexipril group the most common adverse event was cough (8.9%). Conclusion: The results of the study suggest that moexipril and nitrendipine are equieffective in the given dosages. In the patient population of postmenopausal women, the ACE inhibitor moexipril appears to have an advantage over the calcium antagonist nitrendipine with regard to tolerability.

KW - Hypertension

KW - Menopause

KW - Moexipril

UR - http://www.scopus.com/inward/record.url?scp=0033052446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033052446&partnerID=8YFLogxK

U2 - 10.1007/s002280050616

DO - 10.1007/s002280050616

M3 - Article

VL - 55

SP - 185

EP - 189

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 3

ER -